CAMBRIDGE, Mass., Aug. 31,
2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq:
NUVL), a clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for clinically proven
kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer,
and Alexandra Balcom, Chief
Financial Officer, will participate in fireside chats during the
following September investor conferences:
- 2023 Wells Fargo Securities Healthcare Conference on
Friday, September 8, 2023 at
10:15 a.m. ET in Boston;
- Morgan Stanley 21st Annual Global Healthcare
Conference on Wednesday, September 13,
2023 at 8:50 a.m. ET in
NYC.
Live webcasts will be available in the investor section of the
company's website at www.nuvalent.com, and archived for 30 days
following the presentations.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for patients
with cancer, designed to overcome the limitations of existing
therapies for clinically proven kinase targets. Leveraging deep
expertise in chemistry and structure-based drug design, we develop
innovative small molecules that have the potential to overcome
resistance, minimize adverse events, address brain metastases, and
drive more durable responses. Nuvalent is advancing a robust
pipeline with parallel lead programs in ROS1-positive and
ALK-positive non-small cell lung cancer (NSCLC), a program in
HER2 Exon 20 insertion-positive cancers, and multiple
discovery-stage research programs. We routinely post information
that may be important to investors on our website
at www.nuvalent.com. Follow us on Twitter (@nuvalent)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-upcoming-september-investor-conferences-301914280.html
SOURCE Nuvalent, Inc.